An interventional study of Conventional CABG and CABG+ PVI in Arrhythmias, Cardiac, Cardiovascular Diseases and Postoperative Atrial Fibrillation, sponsored by National Research Center of Surgery, Russia. Status unknown at 2 sites in Russian Federation. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-02-06.
Sponsored by National Research Center of Surgery, Russia · Not applicable, Interventional, and Treatment
To compare prophylactic strategies of atrial fibrillation in patients with CAD and without AF.
Prospective, multicenter, randomized trial, intended to compare three prophylactic strategies of atrial fibrillation in patients with coronary artery disease and without history of atrial fibrillation.
The study includes 4 groups of patients:
Group I (conventional CABG)
Group II (CABG + pulmonary veins isolation). Concomitant CABG and epicardial bipolar radiofrequency pulmonary veins isolation.
Group III (CABG+ pulmonary veins isolation + amiodarone). Concomitant CABG and epicardial bipolar radiofrequency pulmonary veins ablation with administration of amiodarone in postoperative periode.
Group IV (CABG+ amiodarone). Conventional CABG with administration of amiodarone in postoperative periode.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 280 is above the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →National Research Center of Surgery, Russia is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
Procedure: Conventional CABG
CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
Procedure: CABG+ PVI
CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
Procedure: CABG+ PVI+amiodarone
CABG+class III antiarrhythmic drug- amiodarone, group, n=70
Procedure: CABG+amiodarone
Coronary artery bypass grafting
CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
Incidence of atrial fibrillation after CABG
Time frame: Through study completion, an average of 1 year
Major cardiovascular and cerebral events (MACCE), including death, nonfatal myocardial infarction, repeated revascularization using PCI or CABG, transitory ischemic attack (TIA) or stroke.
Time frame: Through study completion, an average of 1 year
Sinus rhythm at the time of discharge of the patient from the hospital
Time frame: Through study completion, an average of 1 year
Duration of mechanical ventilation
Time frame: Through study completion, an average of 1 year
Incidence of implantation of the pacemaker
Time frame: Through study completion, an average of 1 year
Volume of intraoperative bleeding
Time frame: Through study completion, an average of 1 year
Time of CBP
Time frame: Through study completion, an average of 1 year
Time clamping of the aorta
Time frame: Through study completion, an average of 1 year
Length of stay in the intensive care unit
Time frame: Through study completion, an average of 1 year
Duration of the hospitalization
Time frame: Through study completion, an average of 1 year
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Research Center of Surgery, Russia